Selenocystine-induced apoptosis in human leukemia Sup-T₁ cells. by Wong, Wing Yin. & Chinese University of Hong Kong Graduate School. Division of Life Sciences.
Selenocystine-induced Apoptosis in Human Leukemia 
Sup-Ti Cells 
WONG, Wing Yin 
A Thesis Submitted in Partial Fulfilment 
of the Requirements for the Degree of 
Master of Philosophy 
in 
Food and Nutritional Sciences 
The Chinese University of Hong Kong 
October 2010 
統系馆 ,囷 \，、 
fef 2 9 AUG ZOlTjll 
Thesis/ Assessment Committee 
Professor Hau Yin Chung (Chair) 
Professor Yum Shing Wong (Thesis Supervisor) 
Professor Peter Chi Keung Cheung (Committee Member) 
Professor Sui-Lam Wong (External Examiner) 
Acknowledgements 
I would like to express my heartfelt gratitude to my supervisor Prof. Y. S. Wong, who 
has given me guidance, patience and selfless support since my final year project and 
throughout the entire period of investigation of M. Phil project. 
My gratitude is also extended to my Thesis Committee members, including Prof. 
Anthony H.Y. Chung, Prof. Peter C.K. Cheung and Prof. S丄 Wong for sparing their 
valuable time to assess my project progress and to give me valuable comments and 
opinions to facilitate my study throughout these two years. 
I would also like to express my greatest gratitude to Dr. Lawrence C.M. Chiu. I am 
grateful to have the chance of being a laboratory helper since my undergraduate 
studies which has undoubtedly widened my horizons and nurtured my interests 
towards scientific research. During the five-year-research-life, Dr. Chiu has always 
supported me and granted me chances to experience about scientific research. Dr. 
Chiu has also actively participated in following up my research progress and 
enlightened me with precious advice. Without his guidance and support during my 
research years, my research life would not be complete. 
I would also like to devote my respect to Mr. Dickson T.S. Ho for his teaching and 
support. He has taught me the basics of research techniques and good research 
practice which definitely facilitate my research during my M. Phil study. 
Besides, I would like to devote my respect to my beloved labmates for their 
enthusiastic help and supports throughout the research journey, including Miss S.N. 
Lim, Miss W.S. Ho, Mr. Dickson T.S. Ho, Miss Ceci W.S. Lam, Miss Jennie Y.P. Ho, 
i 
Miss K.F. Tong, Mr. K.T Leung, Miss Iris S.W. Tong, Miss J.Y. Xue, Miss Shirley S. 
Gao, Mr. C.F. Wong, and Miss Natalie W.S. Lau. Miss Carrie K丄.Kong, Miss Anita 
W.Y. Li, Mr T.F. Chen and Miss Daisy S.Y. Choi have actively discussed my project 
with me and enlightened me with new ideas. I deeply appreciate my labmates who 
have given me enormous support; both technically and spiritually, making the 
two-year M. phil study a fruitful and unforgettable experience, 
I am grateful to my family and friends for their encouragement, understanding, 
support and love which have walked'me through the five-year research life. 
ii 
Abstract of thesis entitled: 
Selenocystine-induced Apoptosis in Human Leukemia Sup-TiCells 
Submitted by Wong Wing Yin 
for the Degree of Master of Philosophy in Food and Nutritional Sciences 
at The Chinese University of Hong Kong in July 2010 
Selenium is an essential micronutrient for human and animals. It functions in the 
active site of a large amount of selenium-dependent enzymes, for instance, glutathionine 
peroxidase, crucial for physiological functions to maintain health. Epidemiological, 
preclinical and clinical studies suggest selenium as a potential cancer chemopreventive 
and chemotherapeutic agent. Previous studies have shown that apoptosis was critical in 
mediating the anticancer activity of selenium. However, its mechanism of action of 
various forms of selenocompounds has not been fiilly elucidated. 
Selenocystine (SeC), a novel organic selenocompound, exhibited growth 
inhibition in leukemic cells first arresting cell cycle at S phase. Apoptosis was then 
followed, confirmed by PARP cleavage and DNA fragmentation. Caspase-8, the initiator 
caspase of the extrinsic pathway, as well as caspase-9, the initiator caspase of the intrinsic 
pathway were both activated. 
Activation of the intrinsic mitochondrial pathway was evidenced by mitochondrial 
membrane depolarization, and proteolytic action of caspase-9. SeC depleted the 
anti-apoptotic Bcl-2 and BC1-XL protein dose-dependently and elevated the pro-apoptotic 
Bax and Bak protein. Bid is cleaved proteolytically by activated caspase-8 into truncated 
Bid, together with Bcl-2 depletion and Bax and Bak elevation, favor the mitochondrial 
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membrane depolarization and discharge of apoptogenic factors, including cyto c and 
smac/DIABLO, from mitochondria into the cytosol. 
In addition, reactive oxygen species (ROS) has been reported previously to cause 
mitochondrial dysftinction, which was found to be elevated in SeC-treated cells. Addition 
of antioxidants, A^-Acetyl-L-cysteine and glutathione not only scavenged the ROS 
produced, also restored the depolarized mitochondrial membrane, and completely 
blocked the SeC-induced growth inhibition and apoptosis. 
This study provides new insights into the mechanisms of SeC in controlling cell 
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Chapter 1 
Chapter 1. General Introduction 
1.1 Overview of Cancer 
According to the World Health Organization (WHO), in 2000，there are more than 
10 million cases of cancer per year worldwide. In 2003, 1,300,000 new cases of 
cancer was approximated to be diagnosed, and more than 550,000 people would die 
from cancer in the United States alone (Surh, 2003). Undoubtedly, cancer has become 
one of the most devastating diseases worldwide. In 2007，it is estimated that there will 
be more than 12 million new cancer cases and 7.6 million people died of cancer 
worldwide. By 2050, more than 27 million new cancer cases and 17.5 million deaths 
are expected (American Cancer Society). 
Cell is the basic unit which comprises for single-celled organisms to complex 
organisms. In order to maintain the normal functions and tissue homeostasis of an 
organism, cellular activities such as proliferation, differentiation and cell death, have 
to be precisely coordinated and monitored via precise regulation of multiple signaling 
pathways that control such cellular decisions (Sears and Nevins, 2002). 
In particular, homeostasis is maintained through a balance between cell 
proliferation and cell death in multicellular organisms. Tumor, also neoplasm, will be 
formed as a result of progressive increase in the number of dividing cells, if such 
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imbalance is uncorrected. 
Tumors are classified according to the differences in growth patterns, namely, 
benign or malignant. According to Cotran et al, self-limited growth and the lack of 
capability to invade into surrounding or distant tissues (metastasis) are characterized 
by benign tumor (Cotran et al” 1999). On the contrary, malignant tumor, also known 
as cancer, possesses the metastatic ability to degrade extracellular matrix structures, 
such as basement membranes that line blood and lymph vessels, so as to move out 
from the origin, survive the drop in hydrostatic pressure in the microvasculature; 
immune surveillance; and finally settle at the endothelium of secondary site, and 
extravasate out of the vessels and form autonomous lesion (Egan et al.’ 1991). 
Carcinogenesis is termed to denote the development of neoplasia. It is a 
multistep process induced by the action of one or more chemical, physical, biologic, 
and genetic agents on cells. Usually, the process of carcinogenesis could be staged 
into initiation, promotion and progression (Pitot, 1993). 
For malignant transformation, non-lethal DNA damage and subsequently, failure 
in DNA repair both play important roles in malignant transformation of normal cells 
(Malejka and Tretyakova, 2006). Precisely, genes involved in normal homeostatic 
mechanisms that control proliferation and cell death suffer mutational damage which 
results in the activation of oncogenes, which are the genes stimulating proliferation or 
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protection against cell death, and the inactivation of the tumor suppressor genes, 
which are the genes that would normally inhibit proliferation. The initiation of 
carcinogenesis is hence the net effect after the complex interaction between activation 
of oncogenes and inactivation of tumor suppressor genes (Zhivotovsky and Orrenius, 
2006). Cancer arises when clones of mutated cells proliferate inappropriately without 
compensatory apoptosis. (Thompson, 1995). 
1.2. Acute lymphoblastic leukemia 
Acute lymphoblastic leukemia (ALL) is a rapidly progressing malignant 
hematologic disease characterized by the neoplastic proliferation of immature 
lymphoid cells called lymphoblasts, within the marrow space, with consequent 
suppression of normal hematopoiesis. 
Under normal conditions, blasts constitute 5% or less of the healthy bone 
marrow. However, in ALL, abnormally immature blasts multiply continuously, 
progressively constituting 30% - 100% of the bone marrow. The diagnosis of ALL 
requires the prescence of at least 30% lymphoblasts in the bone marrow. Eventually, 
suppression of normal hematopoiesis is caused by the expanded lymphoblast 
population which fills up the bone marrow and prevents the production of healthy red 
3 
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cells, platelets, and mature leukocytes. As a result, anemia, thrombocytopenia, and 
neutropenia develop. The above, if untreated, will become lethal. 
ALL is the most common type of malignancy in children, representing 30% of 
all cancer under the age of 15 and constitutes 80% of the leukemia up to the age of 15. 
In adults, ALL is relatively less common and constitutes 15-20% of all cases of acute 
leukemia (Berg et al” 2000). 
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease as defined by 
clinical characteristics and immunologic techniques. The immunophenotyping of ALL 
blast cells is the major method for classifying ALL subtypes. By detection of 
lineage-specific antigens, ALL blast cells can be subdivided into B-lineage and 
T-lineage acute lymphoblastic leukemia. ALL blast cells that express the B-lineage 
markers can also be subclassified into mature B-cell acute lymphoblastic leukemia 
(B-ALL) and precursor B-cell acute lymphoblastic leukemia (pre-B-ALL). Whereas, 
those express T-lineage markers are generally termed as T-cell acute lymphoblastic 
leukemia (T-ALL) (Foon et al., 1980). Approximately 15% of children and adults 
with ALL are diagnosed as T-ALL, and the rest are of the B-lineage (Pui, 2005). 
4 
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1.2.1 T-cell acute lymphoblastic leukemia 
1.2.LI Chemotherapy 
Chemotherapy is the primary treatment for T-ALL. It is generally divided into 
three phases: induction, intensification, and maintenance. Many patients also receive 
treatment called intrathecal chemotherapy to prevent leukemia from spreading to the 
central nervous system. 
1.2. L2 Induction therapy 
Induction therapy of T-ALL aims to induce complete remission. To achieve 
complete remission, the leukemic burden has to be reduced by 99%. Typically, 4 to 5 
drugs are used for remission induction. The current regimens contain vincristine, 
steroids, and daunorubicin plus either asparaginase or cyclophosphamide. Similar 
outcomes were evidenced from different induction therapy programs, with 
approximately 80-90% of the patients achieve a complete remission (Larson, 2003). 
1,2A3 Intensification therapy 
Intensification therapy is designed to eradicate the rapidly proliferating blast 
cells that are responsible for early relapse. Drugs given for this purpose are usually 
antimetabolites such as methotrexate. The need for intensive intensification therapy to 
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achieve a cure, unlike that of remission induction therapy, is controversial. In 
randomized trials, increasing doses of chemotherapy during intensification therapy 
did not improve the results (Ribeiro and Pui, 2005). 
1.2,1,4 Maintenance therapy 
For maintenance therapy, T-ALL patients receive a prolonged period of treatment 
with low doses of chemotherapeutic drugs. The period of maintenance therapy is 
depended on the intensity and success of the previous phases of chemotherapy. 
Typically, 1 to 3 years of 6-mercaptopurine and methotrexate are often used in this 
phase of therapy (Larson, 2003). 
L2,2 Chemoresistance in T-ALL 
Previous studies have shown that patients with T-ALL have poorer treatment 
success than those with B-lineage ALL. Henze et al. reported that the 9-year 
probability of continuous complete remission were 9% 土 9% and 41% ± 5%, for 
patients with T-lineage ALL and non-T-lineage ALL, respectively (Henze et al” 1981). 
Although treatment outcome in newly diagnosed T-ALL has improved significantly in 
several recent clinical trials (Goldberg et al., 2003; Pui et al., 2004), higher rates of 
induction failure, induction death and early relapse are consistently found in T-ALL 
patients. These clinical data suggest that patients with T-ALL may be more resistant 
6 
Chapter 1 
to conventional chemotherapeutic agents. 
Owing to the remarkable progress in the treatment strategies, T-ALL is now 
curable with chemotherapy in over 80% of patients. However, the cause of treatment 
failure in the remaining patients is still largely unknown. Only a few reports have 
highlighted the underlying mechanisms. The cause of glucocorticoids resistance is 
controversial. Quddus et al. reported that glucocorticoids receptor levels in leukemic 
cell could not be used to predict the treatment outcome (Quddus et al., 1985). 
However, Costlow et al. reported that lower glucocorticoids receptor levels were 
correlated with unfavorable presenting features (Costlow et al” 1982). More recently, 
several differentially expressed genes have been identified in ALL cells with 
resistance to prednisone, vincristine and daunorubicin, whose pattern of expression is 
related to treatment outcome (Holleman et al., 2004). However, it is still not known 
whether modulation of the proteins encoded by these genes will enhance treatment 
efficacy in patients with drug-resistant ALL. 
1.3 Apoptosis and cancer 
Cells have an inherent suicidal program called apoptosis, also known as 
programmed cell death. It represents a universal and exquisitely efficient cellular 
suicidal pathway. Apoptosis is a genetically controlled event essential for embryonic 
development, immune-system function and the maintenance of tissue homeostasis in 
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multicellular organisms (Adams, 2003，Jacobson et al., 1997; Savill and Fadok, 
2000). 
Apoptosis is generally characterized by a stereotypical series of biochemical and 
morphological changes (Elmore, 2007) leading to a combined process of nucleosomal 
fragmentation by endonucleases, widespread proteolysis by cysteine aspartyl-specific 
proteases (caspases) and cell surface tagging to induce phagocytosis. For morphologic 
changes, characteristics such as cell shrinkage, cytoplasmic condensation, chromatin 
segregation and condensation, membrane blebbing, and the formation of 
membrane-bound apoptotic bodies are displayed by apoptotic cells (Loo and Rillema， 
1998). Subsequently, the apoptotic bodies which packed the dissembled materials are 
engulfed by phagocytes, to prevent potential harmful exposure of intracellular 
antigens to the immune system which incurs unnecessary inflammatory response 
(Savill and Fadok, 2000). 
Apoptosis can be initiated by two major pathways: namely the extrinsic 
pathway, mediated by activated death receptors on the cell surface upon binding with 
death-inducing ligands (the extrinsic death receptor pathway) (Broker et al” 2005); 
whereas the intrinsic pathway is mediated by mitochondria, triggered by the release of 
cytochrome c in the mitochondria (the intrinsic mitochondrial pathway) (Krammer, 
1999). Both pathways ultimately converge on activation of caspases, which in turn 
8 
Chapter 1 
cleave cellular death substrates (Darzynkiewicz 1995a; Darzynkiewicz et al” 1997; 
Thomberry and Lazebnik，1998). 
Numerous studies have shown that many types of cancers are defective in 
eliciting the apoptotic pathway. One of the six hallmarks of cancer includes the 
evasion of apoptosis which gives the ability of cancer cells to grow without control 
and metastasize (Debatin and Krammer, 2004; Hanahan and Weinberg, 2000). 
Recent studies have demonstrated that caspase-independent apoptosis also 
played a role in eliminating unwanted cells in an organism, despite 
caspases-activation has been regarded as a hallmark feature in apoptosis. 
Caspase-independent cell death has been defined as the loss of cell viability that is 
induced by pro-apoptotic conditions, and which proceeds despite the inhibition or 
disruption of caspase ftinction, executed via the actions of other proteases that could 
also elicit apoptosis-like cell death (Cande et al., 2004; Chipuk and Green, 2005, 
Stoka et al” 2001). Here, an alternative research direction in the cell death pathways 
of cancer is opened up by the discovery of various models of apoptosis (Broker et al., 
2005) 
1.3.1 Chemoresistance 
Development of malignant tumors originates from the inability of cells to 
undergo apoptotic cell death (Steller, 1995). Since chemotherapeutic drugs act 
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primarily by inducing apoptosis, defects in the apoptotic machinery can make cancer 
cells resistant to therapy. Thus, understanding of how tumor cells resist apoptosis 
might lead to the development of novel therapeutics that target at restoring apoptosis 
sensitivity (Igney and Krammer, 2002). 
1.4 Caspase-dependent apoptosis 
1.4.1 Regulation of caspase-dependent apoptosis 
Caspases are a family of intracellular cysteine proteases that cleave their 
substrates specifically following an aspartate residue (Thomberry and Labzenik, 1998; 
Kumar，2007). Caspases function in a proteolytic cascade where each caspase can 
either activate itself or other caspases. Fourteen caspases have been identified in 
mammalian cells, of which 11 enzymes are known of human origin (Lamkanfi et al., 
2002). These enzymes are synthesized as precursor inactive zymogens, that upon 
receival of apoptotic signals, must be proteolytically processed at conserved aspartate 
residues to generate the active tetrameric enzyme (Nicholson, 1999，Degterev et al” 
2003). The caspase-dependent apoptotic cascade generally involves two subtypes of 
caspases: the initiator caspases (caspase-2, -8，-9 and -10) characterized upstream of 
and in turn activate the downstream effector caspases (caspase-3, -6 and -7) which are 
responsible for the direct destruction of cellular materials. In the intrinsic 
mitochondrial pathway, caspase-9 is regarded as the leading caspase; whereas in the 
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death-receptor mediated apoptosis, caspase-8 is the key initiator (Kumar, 2007). Other 
enzymes (caspase-1, -4, -5, -11, -12 and -14) are mainly involved in cytokine 
maturation and inflammation (Vermeulen et al., 2005; Chang and Yang, 2000). Two 
apoptotic pathways can be triggered: the extrinsic death-receptor pathway and the 
intrinsic mitochondrial pathway by caspase activation. 
1.4.2 Initiation of apoptosis 
Apoptosis can be initiated by two distinct pathways. The extrinsic pathway 
is mediated by death receptors on the cell surface. The intrinsic pathway is mediated 
by mitochondria (Krammer, 1999). Both pathways ultimately converge on the 
activation of cysteine aspartyl-specific proteases (caspases). Activated caspases in 
turn cleave cellular death substrates, resulting in the biochemical and morphological 
changes that are hallmarks of apoptosis. 
1.4.3 Extrinsic pathway 
The extrinsic pathway is activated by the engagement of death-inducing ligands 
with their death receptors on the cell surface. Death receptors are members of the 
tumor necrosis factor (TNF) receptor superfamily. Members of this TNF receptor 
family are diverse in primary structure but they are characterized by the presence of 
up to six copies of a cysteine-rich domains in their extracellular part that are thought 
to adopt generally similar tertiary folds. Nevertheless, it is the unique structural 
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features of individual family members that allow them to recognize their ligands with 
specificity and, in most cases, exclusivity (Naismith and Sprang, 1998). Twenty 
proteins classified into this family which has broad range of biological functions 
including cell death and survival regulation, differentiation and immunoregulation 
(Walczak and Krammer, 2000). Six members have been identified in this family 
including TRAMP (DR3/Apo-3), DR6，and the best characterized members of the 
family CD95 (APO-l/Fas), TNF receptor 1 (TNFRI), TRAIL-Rl (DR4) and 
TRAIL-R2 (DR5). Besides sharing the one to four cysteine rich domains (CRDs) 
extracellularly, these family members also share an 80-amino-acid cytoplasmic 
domain designated as the 'death domain', which serves a crucial importance in the 
transmission of death signals to the intracellular signaling cascade (Bossen et al” 
2006). 
Adapter-molecules like FAS-associated death domain (FADD), TNF 
receptor-associated death domain (TRADD) or death domain-associated protein 
(DAXX) themselves also contain death domains so that they can interact with the 
death receptors and transmit death signals to the intracellular signaling cascade 
(Bossen et al., 2006). 
The death-inducing ligands are related cytokines that include CD95 ligand/FasL, 
TNFa and TNF-related apocing ligand (TRAIL). With some less characterized 
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exceptions, almost all death-inducing ligands are type II transmembrane proteins. The 
ligands can also exist in free and soluble form by the proteolytic action of 
metalloproteases in the environment (Herr et al.’ 2000). They function in an autocrine 
and paracrine manner to mediate the ligation with the surface death receptors (Sheikh 
and Fomace Jr., 2000). In order to elicit a cell death signal from the cell surface to the 
cytoplasm, the death receptors have to be independently activated via their 
corresponding death-inducing ligands. 
Although ligation between death receptor and corresponding ligand is believed 
to be the activation of extrinsic pathway, some evidence has also suggested the 
possibility of ligand-independent activation of death receptors (Sheikh et al” 1998; 
Peter and Krammer, 2003). 
Upon activation of death receptors by death-inducing ligands, the ligands first 
trimerize to form a trimeric ligand cluster before ligation to corresponding death 
receptors. The engagement of ligand cluster to death receptor further induces the 
trimerization of death receptors from the original monomelic conformation. Once the 
receptor is activated, the adaptor protein will then be recruited to the activated 
receptor via the interactions of the respective death domains (Sheikh and Huang, 
2004). Once associated with the death receptor, the adaptor protein can further 
interact with procaspase-8 or -10, leading to activation of the initiator caspases by 
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oligomerization-mediated activation (Askkenazi and Dixit, 1999). The association of 
the death-inducing ligand, death receptor, adaptor protein and initiator caspase forms 
an active, death inducing complex called death-inducing signaling complex (DISC). 
The DISC formation thus activates the downstream caspases and the subsequent 
apoptotic events by the active initiator caspases (Debatin and Krammer, 2004). 
Oligomerization of pro-caspase-8 in the DISC autoactivates and releases mature 
caspase-8, which functions as an initiator caspase (Salvesen and Dixit, 1999). 
Downstream of caspase-8 activation, apoptosis induction takes place in a cell-type 
specific manner. In some cell types, designated as type I cells, caspase-8 processes 
and activates effector caspases, especially caspase-3, directly with efficiency 
sufficient to ensure apoptotic cell death. However, in type II cells, the small amount of 
active caspase-8 is insufficient to initiate apoptosis directly. Apoptosis induction by 
Disc-mediated caspase-8 activation is dependent on an amplification loop, which is 
triggered by caspase-8-mediated cleavage of Bid, a BH3 domain-only member of the 
Bcl-2 protein family, to generate an active fragment, tBid, which can induce Bax and/ 
or Bak-mediated release of cytochrome c, subsequently activate the intrinsic apoptosis 
pathway (Scaffidi et al” 1999). 
14 
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1.4,4 Intrinsic mitochondrial pathway 
The intrinsic apoptosis pathway is triggered by both extracellular and intracellular 
stresses, such as growth-factor deprivation, hypoxia, DNA damage, and oncogene 
activation, converging mainly on the mitochondria (Crighton and Ryan, 2004). Upon 
stimulation by such stress-induced death signals, a series of biochemical events is 
induced ultimately in the mitochondria leading to the mitochondrial outer membrane 
permeabilization (Kluck et al., 1999). 
Mitochondrial outer membrane permeabilization may be considered the point at 
which the cell is irreversibly committed to death by apoptosis. Following the 
permeabilization of the outer mitochondrial membrane, a series of biochemical events 
is induced which include the release of apoptogenic factors, formation of the 
apoptosome which is a large protein complex containing cytochrome c (cyto c), 
apoptotic protease activating factor-1 (apaf-1) and caspase-9, and caspase activation 
(Budihardjo et al., 1999). 
The mitochondrial outer membrane permeabilization is primarily regulated by the 
Bcl-2 family proteins to determine the cell's decision to commit suicide by apoptosis 
(Cory and Adams, 2002). Once cyto c is released, the downstream caspase cascade is 
irreversibly activated (Goldstein et al., 2000). This pathway can also be amplified by 
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caspase-8-mediated cleavage of Bid to truncated Bid that then activates Bax or Bak. 
Thus, Bid connects the extrinsic to the intrinsic apoptosis pathway (Heir and Debatin, 
2001; Daniel et al., 2003). 
As mitochondrial dysfunction and the subsequent release of apoptogenic factors 
mark the “point of no return" in apoptosis (Hangartner, 2000)，the normal functions 
and the intergrity of the mitochondria should therefore be precisely regulated. 
1-4.4,1 Regulation of apoptosis by Bcl-2 family proteins 
The Bcl-2 family of proteins has been regarded as the central regulator of 
mitochondrial pathway (Ghobrial et al., 2005), shown by their indispensable roles in 
caspase activation, and its opposing factions of anti- and pro-apoptotic members 
orchestrate the life-or-death decision (Skommer et al, 2006). Apoptosis is stringently 
controlled and can be regulated by different classes of molecules at various levels. At 
the mitochondrial level, apoptosis can be regulated by members of the Bcl-2 family 
proteins. According to Cory and Adams, over 20 molecules that can be classified 
functionally into anti-apoptotic and pro-apoptotic members were identified in the 
human Bcl-2 family (Cory and Adams, 2002). Structural analyses identified four 
highly conserved homologous regions in family members. These are the Bcl-2 
homology (BH) domains BHl, BH2, BH3 and BH4 that are essential for the homo-
and hetero-complex formation among the family members that directly affecting the 
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apoptosis-induction capacity. Anti-apoptotic members are Bcl-2, BCI-XL, Bcl-w and 
Mcl-l that serve at the mitochondrial outer membrane in preventing the release of 
mitochondrial cytochrome c into the cytosol. 
Structural and functional analyses revealed that the growing Bcl-2-homologous 
genes can be divided into at least three distinct subfamilies: the Bcl-2 and the Bax 
subfamily, and the BH3-only proteins (Adams and Cory, 1998). 
The pro-apoptotic Bcl-2 family members can be organized into 2 subfamilies, (i) 
the Bax homologues, including Bax, Bak, and Bok which share sequence homology 
among the BHl, BH2 and BH3 domains, (ii) the BH3-only subfamily comprises Bad, 
Bid, Noxa, Puma, Bik, Bim, Bmf, and Nip-3. BH3-only proteins serve as sensors of 
cellular damage and in response, initiate the death process. 
At transcriptional level, the Bcl-2 subfamily, functions as potential oncogenes 
that promotes cell survival. The two anti-apoptotic proteins, Bcl-2 and its 
anti-apoptotic homolog BC1-XL, modulate cell death primarily by inhibiting the release 
of cytochrome c and other mitochondrial events (Tudor et al., 2000). Subsequently, 
formation of apoptosome and the subsequent activation of caspases are counteracted 
by Bcl-2 and BC1-XL. In addition, Bcl-2 proteins expression stabilizes the 
mitochondrial transmembrane potential, via proton flux regulation, inhibition of 
generation of reactive oxygen species (ROS), and prevention of cytosol acidification 
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(Schendel eta!” 1998). 
In the Bax subfamily, pro-apoptotic proteins: Bax and Bak act as accelerators of 
apoptosis. During induction of the mitochondrial pathway, near the time of 
commitment to cell death and synchronize with the release of cytochrome c, Bax and 
Bak become activated and undergo a conformational switch in the N-terminus and the 
C-terminus that results in redistribution of Bax into the outer mitochondrial 
membrane. Bax translocation to the mitochondria coincides with oligermerization of 
Bax to multimeric complexes. Likewise, recombinant Bax oligomerizes and forms 
channels in artificial liposomal membranes. Such Bax oligomers possess 
channel-forming properties that are associated with ion fluxes and consecutive loss of 
the mitochondrial membrane potential. In contrast, Bak resides constitutively in the 
mitochondrial membrane and the ER, where it oligomerizes upon activation. This 
conformational change of Bax/ Bak plays an essential role in the perforation of 
mitochondrial outer membrane (Antignani and Youle, 2006). Consequently, ion fluxes 
and consecutive loss of the mitochondrial membrane potential occur. 
BH3-only proteins which carry only one BH3 domain may function as death 
sensors and their pro-apoptotic activity is subject to stringent control. For example, 
Noxa and Puma are transciptionally induced by p53 upon stress conditions. BH3-only 
proteins induce mitochondrial permeabilization either by inhibiting the anti-apoptotic 
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proteins or by activating pro-apoptotic proteins of the Bax subfamily (Bouillet and 
Strasser, 2002). Meanwhile, many other BH3-only proteins are present in healthy 
cells in a dormant form and are activated upon post-translation modification, such as 
phosphorylation of Bad. Bim is regulated by sequestration to cytoskeletal structures 
(Puthalakath and Strasser, 2002). During apoptosis mediated upon ligation of death 
receptors, Bid is proteolytically cleaved by caspase-8 to a pro-apoptotic form (tBid) 
from an inactive form. tBid appears to interact physically with Bax to mediate a 
conformational change in Bax N-terminus (Danial and Korsmeyer, 2004), which 
triggers insertion of cytosolic Bax into the outer mitochondrial membrane and thus 
disrupts the mitochondrial integrity (Eskes et al.，2000). Thus, Bid links 
death-receptor signaling to the mitochondrial pathway. The well-studied members of 
this subfamily include Bad and Bid. Pro-apoptotic Bad protein interacts via its BH3 
domain with Bcl-2 and BC1-XL to facilitate the actions of apoptotic stimuli (Tudor et 
al., 2000). 
1,4.4.2 Reactive Oxygen Species (ROS) 
ROS such as superoxide and the hydroxyl radical, generated by mitochondria, 
are produced as by-product of normal oxidative metabolism. ROS has been recently 
identified to play a regulatory role in apoptosis (Ott et al” 2007). ROS describes small 
and highly reactive molecules with unpaired valence shell electrons, which include 
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oxygen ions, free radicals and peroxides (Sen, 2003). Intracellular ROS is formed as a 
natural byproduct of the normal metabolism of oxygen in the mitochondria, which is 
the power house of the cell. Hence, the mitochondria would therefore be the primary 
site of production of ROS by oxidative phosphorylation (Storz, 2007). 
The overall system of oxidative phosphorylation includes five large multienzyme 
complexes, designated as complexes I, II, III，IV and ATP synthase. In particular, 
NADH dehydrogenase at complex I，and the interface between CoQ and complex HI 
at the inner membrane of mitochondria are the two main sites of superoxide 
generation in this system (Nishikawa et al., 2007). 
Superoxide is the product of the addition of an electron to oxygen. This product 
can react with iron-sulphur centres containing enzymes leading to the release of iron. 
Once the superoxide is formed, it will rapidly discharge through the mitochondrial 
matrix to the cytosol where it is removed rapidly by conversion to H2O2 in a reaction 
catalysed by superoxide dismutase. Under normal circumstances, the cellular 
antioxidant defense system functions to eradicate the excess ROS produced. 
Manganese superoxide dismutase (MnSOD) detoxifies cells from superoxide released 
into the mitochondrial matrix, and the copper/zinc superoxide dismutase (Cu/ZnSOD) 
from cytosolic superoxide (Crompton, 1999). Moreover, water- and lipid- soluble 
vitamins are also powerful antioxidant to serve the purpose. Mitochondria itself can 
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also contribute to the antioxidant defense by the oxidation of succinate (Orrenius et al.’ 
2007). 
Oxidative stress to the cells happens when the damaging ROS cannot be 
eradicated by the innate antioxidative mechanisms (Liu et al., 2002). Accumulation of 
ROS exerts devastating effects on the cells, such as oxidation on the polyunsaturated 
fatty acids in phospholipids on membranous structure (Hernandez-Hernandez, 2005), 
damage on genomic DNA (Tsuzuki et al” 2007) and alteration of protein 
conformation (Sohal, 2002). Moreover, ROS is also able to trigger the mitochondrial 
mediated apoptotic pathway. 
Being the first target of ROS, mitochondrial DNA (mtDNA) is crucial in 
encoding proteins and RNAs, indispensable in regulating electron transfer and 
oxidative phosphorylation (Fleury et al.，2002). For instance, histone-free mtDNA 
situated closely to the site of ROS production, being more susceptible to ROS damage, 
when damaged directly leads to mitochondrial dysfunction (Orrenius et al., 2007) 
Second, ROS oxidizes mitochondrial proteins that play vital roles in the electron 
transport chain. Superoxides impose toxicity via oxidation and inactivation of 
iron-sulfur (Fe-S) proteins, e.g. aconitases, and release of Fe^ "^  ions (Fridovich, 1997). 
Further oxidative burden is posed to the cells when release of Fe^^ ions is 
simultaneous with the release of H2O2, (Liochev and Fridovich, 1999), which 
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produces hydroxyl radical. It is a very damaging product that causes peroxidation of 
mitochondrial proteins, lipids and DNA, worsening the overall oxidative damage. 
Third, ROS peroxidates mitochondrial lipid. Lipid peroxides causes impairment 
of mitochondrial functions: respiration and oxidative phosphorylation, inner 
membrane barrier properties, maintenance of mitochondrial membrane potential 
(A中m)，and mitochondrial Ca^^ buffering capacity (Cejas et al, 2004; Venditti et al., 
2004). 
The release of cytochrome c is undoubtedly crucial in the mediation of 
mitochondrial apoptotic pathway, (Slee et al” 1999). Cytochrome c release is 
mediated by ROS via the peroxidation of cardiolipin (Ott et al., 2007). Cardiolipin, 
compositing phospholipids in the mitochondrial membranes, stabilizes cytochrome c 
and other electron transport chain-related proteins in the intermembrane space 
(Tuominen et al, 2002), also confers fluidity and mobility of the mitochondrial 
membrane (Ott et al” 2007). It was early found that intracellular ROS accumulations 
brings about cardiolipin oxidation which decreases its binding affinity for cytochrome 
c and facilitates cytochrome c mobilization from the intermembrane space (Ott et al., 
2002). 
The role of ROS in the induction of apoptosis, particularly the mitochondrial 
mediated pathway, has been postulated and supported by numerous scientific 
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evidences. Being highly toxic molecules, ROS mediates cell death pathway via a 
variety of cell death paradigms that wait to be folly elucidated. Being a primary 
source of cellular ROS and susceptible to ROS-induced damages, mitochondrion is 
stringently regulating ROS levels in order to maintain its normality, and circumvent 
itself from apoptosis induction. 
1.5 Selenium 
Selenium (Se) is an essential trace element of fundamental importance to 
human and many other forms of life (Rayman, 2000). Se has six naturally occurring 
isotopes, five of which are stable, including ^^Se, ^^Se, "^ S^e, ^^Se, and Several 
oxidation states have been identified for Se, for instance, 0 for elemental Se, +IV for 
selenite, and +VI for selenate (Reilly, 1996). 
Selenium (Se), as an essential micronutrient for human and animals, functions 
in the active site of a large number of selenium-dependent enzymes, such as 
glutathione peroxidase (Miller et al” 2001，Ip et al.’ 2000). For instance, the redox 
functions of selenium-dependent glutathione peroxidase in the reduction of hydrogen 
peroxide and phospholipids hydroperoxides. Se has been shown to affect the functions 
of several specific intracellular selenoproteins by being a component of their essential 
constituent, selenocysteine (SeCys) (Allan et al,, 1999). Over 35 selenoproteins have 
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been identified in which Se serves structural and enzymatic roles (Spallholz et al., 
1990) which include mitochondrial capsule selenoprotein, thioredoxin reductases, 
selenophosphate synthetase, selenoprotein P, selenoprotein W, prostate epithelial 
selenoprotein (Rayman, 2000). Organic Se is present in foods mainly in the form of 
selenomethionine, selenocysteine and semethylselenocysteine, whereas inorganic Se 
either as seleinite or selenate occurs much less frequently and in very low amounts. 
Most human dietary Se requirement is met by dietary selenomethinonine and, the 
lesser amounts of seleoncysteine, both of which are components of animal proteins. 
Both organic selenomethionine (as a component of Se-enriched yeast) and inorganic 
selenite (SeOa ") are commercial forms available as supplements, also taken up from 
the diet. Most of the early studies of Se cancer chemoprevention have used either 
sodium selenite or selenomethionine (SeM) as the target selenocompounds (Fig. 1). 
However, latter studies showed that Se-methylselenocysteine (SeMC) and 
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Fig. 1 • 1 Chemical structure of selenocompounds 
A 5.7. Importance of Se to human health 
Low serum Se 
increases the risk of miscarriages in women (Barrington et al., 
1996) and decreases the sperm motility and chances of fertilization in men (Scott et 
al” 1998). Rheumatoid arthritis, pancreatitis and asthma might also be influenced by 
Se levels (McCloy, 1998, Knekt et al., 2000). Myriad studies suggest that Se 
deficiency is related to loss of some immuno-competency (Spallholz et al., 1990). 
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Diseases associated with oxidative stress are possible to be influenced by dietary Se 
and its enzyme levels (Rayman, 2000). In some regions of China, such as 
Heilongjiang, Jilin, Neimeng and Yunnan provinces, Keshan disease, an endemic 
cardiomyopathy, and Kashin-Beck disease, a deforming arthritis, are both typical 
Se-deficiency diseases, which have been identified (Rayman, 2000). 
One of the most important features of Se is the very narrow margin between 
nutritionally optimal and potentially toxic dietary exposures for vertebrate animals 
(Wilber, 1980). Overabundance and depletion may cause serious biological and 
ecological problems, such as Se toxicosis and chronic Keshan disease (Fordyce et al” 
2000). The initial US recommended daily allowance in 1989 was 50-70 ^ig/day for 
healthy human adults and has been lowered to 55 ^g/day at present (Whanger, 2004, 
El-Bayoumy, 2001). This amount of Se may fulfill the dietary need for the 
selenoproteins as well as for general human health. Concerning the toxicity, Se has 
limited doses used in chemoprevention. Human studies suggest an intake of 400 
[ig/day showed no observed adverse effect and was established as the maximum safe 
dietary dose. In vitro studies showed that both the dose and chemical form of Se 
compounds are critical for cellular responses (Ip，1998). Se compounds at low 
concentration may have protective anti-carcinogenic properties, whereas at high 
concentrations they can be genotoxic and possibly carcinogenic (Spallholz, 1994). 
26 
Chapter 1 
7.5.2 Cancer chemoprevention by Se 
Epidemiological studies, preclinical investigation and human clinical 
intervention have supported a protective role of Se against cancer development 
(Meuillet et al., 2004, Greenwald, 2004，El-Bayoumy, 2001, Duffield-Lillico et al., 
2002). 
Shamberger and Frost hypothesized that Se status can be inversely related to the 
risk to some kinds of cancer (Shamberger and Frost, 1969). For instance, dietary 
intake of Se in 27 countries showed a significant inverse correlation with age-adjusted 
mortality for cancer of the colon, prostate, breast, ovary and lung as well as with 
hematopoetic cancers (Schrauzer et. al., 2000). Furthermore, low Se status was 
reported as a risk factor for lung cancer in a nested case-control study conducted in 
Finland on 9000 individuals (Knekt et al., 1998). Solid confirmation was brought 
about by more than 100 experimental studies on different forms and doses of Se 
(Combs and Gray, 1998). In conclusion, the encouraging observations from 
epidemiological studies stimulated the interest in testing the possibility of Se as a 
chemopreventive agent in human clinical trials (Meuillet et al., 2004). 
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1.5.3. Preclinical studies 
In over 100 preclinical studies, two-thirds of the results showed reductions in 
the incidence of tumor growth, in which half showed reductions of 50%, which brings 
into conclusion that high-level exposure to at least some Se compounds can be 
anti-tumorigenic (Combs and Combs, 1998; El-Bayoumy, 2001). Among the various 
natural and synthetic selenocompounds examined as chemopreventive agents in 
several animal tumor models, organoselenium compounds have been found as better 
chemopreventive agents in several animal tumor models compared with inorganic Se 
compounds (Ip, 1998, El-Bayoumy, 2001, Combs and Gray, 1998). 
1.5.4. Clinical investigations 
In China and the U.S., chemoprevention trials have been conducted with Se in 
the form of selenite, selenate, or selenium-enriched yeast (Yu et al” 1991, Yu et al., 
1997，Clark et al., 1996,). In the U.S., the Nutritional Prevention of Cancer (NPC) 
trial carried out by Clark et al, (1996) on 1312 individuals with a history of 
non-melanoma skin cancer were randomized to placebo or 200 i^g Se per day as 
selenium-enriched yeast. The study aimed at testifying whether Se supplementation 
could reduce the risk of skin cancer, although no effect was observed on 
non-melanoma skin cancer, yet individuals in the Se-treated group showed sizable 
reductions in the risk of colon, rectum, prostate and lung cancers, in particular, the 
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prostate cancer incidence decreased significantly by 65% (Duffield-Lillico et al” 
2002). In China, clinical intervention trials supported the anticancer efficacy of Se. 
For instance, in Qidong, daily supplement of 200 i^g Se as Se-enriched yeast 
eliminated liver cancer incidence among hepatitis surface-antigen carriers (Yu et al” 
i991, Yu et al” 1997). Similarly, in Linxian, Henan Province, a daily supplement of 
50 Se as Se-enriched yeast for individuals in an area with a high prevalence of 
esophageal cancer, showed protective effects against stomach cancer mortality, total 
cancer mortality and total mortality (Li et al., 1993). 
/•5.5 Mechanisms of action by selenocompounds 
At supranutritional dietary levels, Se can prevent the development of many 
types of cancers. At higher concentrations, Se compounds can be either cytotoxic or 
possibly carcinogenic. The cytotoxicity of Se compounds is now viewed as being 
caused by the generation of reactive oxygen species (ROS) (Stewart et al., 1999) 
Anticancer action of Se, has been proposed to be anticipated by protection 
against oxidative stress, detoxification of carcinogens, stimulation of the immune 
system, effects on the cell cycle distribution, induction of apoptosis, modulation of 
thioredoxin reductase activity, maintenance of cell redox balance, inhibition of 
angiogenesis (Zhao et. al., 2006). 
In particular, cell apoptosis have been postulated to be critical for cancer 
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chemoprevention by selenocompounds (Sinha and El-Bayoumy, 2004). Previous 
studies showed Se，in the chemical forms of selenite, selenate, methylseleninic acid, 
selenomethionine and Se-methylselenocysteine, could induce extrinsic or intrinsic 
apoptotic signaling in a number of cancer cell types via alteration of expression or 
activities of mitochondria-associated proteins, cell cycle regulatory proteins, proteases, 
signaling proteins, angiogenic factors and transcription factors (Rikiishi, 2007). 
According to Singh et al, the uncontrolled growth of pre-neoplastic or neoplastic 
cells is partially due to the malfunctioning or dysregulation of their cell-growth and 
cell-death machineries (Singh et al., 2002). Therefore, inhibition of deregulated cell 
cycle progression in cancer cells is an effective strategy to halt tumor growth. 
Selenocompounds, such as sodium selenite, selenomethionine and 
methylseleninic acid, elicit cell-cycle arrest at Go/i and G2/M phases in human prostate 
and colon cancer cells, as well as vascular cancer epithelial cells, through the 
induction of cyclin-depedent kinase inhibitors: CDKIs (p21 and p27) and tumor 
suppressor protein: p53, and inhibition of cyclins and cyclin-depedent kinases: CDKs 
(Zhong and Oberley，2001，Wang et al.’ 2008, Venkateswaran et al.’ 2002, Jiang et al., 
2002, Goel et al., 2006) 
For T-cell acute lymphoblastic leukemia, sodium selenite was previously 
reported to induce cell cycle arrest and apoptosis in human lymphoblastic leukemia 
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(Philchenkov et al” 2007). 
1.6 Aims of current study 
Approximately 20% of the patients with T-ALL are not responsive to the current 
chemotherapeutic regimens, and these patients will eventually die of the disease. 
Unfortunately, the cause of treatment failure in these patients remains largely 
unknown. As chemotherapy acts primarily by inducing apoptosis, defects in the 
apoptotic pathway may also contribute to the chemoresistance in at least some 
T-ALL patients. Using cell-based models, we aim to investigate the molecular 
mechanisms of selenocompound that can overcome resistance to drug-induced 
apoptosis in T-ALL patients. Findings of this study would be expected to facilitate 




Chapter 2. Materials and Methods 
2.1 Cell culture 
The human T-ALL cell lines, HSB-2, MOLT-3 and Sup-Ti were obtained from 
the American Type Culture Collection (Rockville, MD). HSB-2 was derived from a 
buffy coat preparation from a patient with ALL (Adams et al” 1968). MOLT-3 was 
established from a T-ALL patient in relapse (Minowada et al., 1972). Sup-Ti was 
derived from malignant cells collected from pleural effiision of an 8-year-old child 
with T-ALL (Smith et al., 1988). All cell lines were grown in RPMI-1640 medium 
(Sigma, St. Louis, MO) supplemented with 10% heat-inactivated fetal bovine serum 
(Gibco，Rockville, MD), 1.5 g/L sodium bicarbonate, 1 mM sodium pyruvate, 10 mM 
HEPES (7V-2-hydroxy- ethylpiperazine-7V'-2-ethanesulfonic acid), 100 U/mL 
penicillin and 100 |ig/mL streptomycin. The cells were maintained in 5% CO2 at 37 
2.2 Measurement of growth and survival of T-ALL cell lines 
MTT assay was applied to examine the effects of various selenocompounds 
namely sodium selenate, sodium selenite and selenocystine (Fluka) on cell growth 
control. 0 to 80 i^M of sodium selenite and selenocystine, 0 to 800 jiM of sodium 
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selenate were incubated with a panel of T-ALL cells, including, Sup-Ti, HSB-2 and 
MOLT-3 for 72 h，which were then analyzed by MTT assay. Cancer cells were seeded 
in 96-well round bottom culture plates at an initial number of 5 x 10^/mL respectively. 
After 72 h incubation of various selenocompounds, 20 |JL of the MTT solution was 
added to each well and further incubated for 5 h. The MTT solution was freshly 
prepared by dissolving MTT (Sigma) in filtered phosphate-buffered saline (PBS) at 5 
mg/ml. After 5 h of incubation, the wells were carefully aspirated and the blue 
formazan formed was dissolved by adding 150 |LIL dimethyl sulphoxide ( D M S O ) . All 
the wells were then mixed by pipetting until all crystals were dissolved completely. 
Absorbance of the blue formazan solution generated was measured at 570 nm by the 
microplate reader. The inhibitory effect of SeC on the tested cell lines was expressed 
as percentage inhibition, which was calculated by the following equation: 
广 Average absorbance of treatment group � 
1 - X 100% 
� Average absorbance of control group � 
The percentage inhibition calculated was plotted against the corresponding 
concentration of SeC tested on the tested cell lines were expressed as percentage 
inhibition, which was calculated by the above equation. The inhibitory effects of 




2.3 Induction and quantification of apoptosis 
To induce apoptosis, the leukemic cells were seeded at an initial density of 1.5 x 
105 cells/mL and treated with or without 5 i^M, 10 i^M, 20 i^M, 40 ^M or 80 [LM 
selenocystine (Fluka) for the indicated time points. After treatment, the cells were 
washed with phosphate-buffered saline (PBS) and fixed in 70% ethanol at -20 °C for 
24 h. The cells were next incubated in dark for 30 min with 1 mg/mL ribonuclease A 
(RNase A; Sigma) and 10 |ig/mL propidium iodide (PI; Sigma). Samples were 
analyzed for DNA content by measuring PI fluorescence on the Epics XL-MCL flow 
cytometer (Beckman Coulter, Miami, FL). Cell cycle distribution was analyzed using 
Multicycle software (Phoenix Flow Systems, San Diego, CA). Cells displaying 
hypodiploid DNA content were quantified and regarded as the apoptotic population. 
For each experiment, 10,000 events per sample were recorded. 
2.4 Western blotting 
2,4.1 Protein extraction and determination of protein concentration 
For preparation of whole cell lysates，cells were treated with 5, 10 and 20 i^M 
SeC for 72 h, harvested and suspended for 30 minutes on ice in an extraction buffer 
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(20 mM Tris-HCl at pH 8.0，150 mM NaCl，5 mM EDTA, 0.2% BSA, 1% Triton 
X-100) supplemented with protease inhibitors (BD Biosciences, San Jose, CA). 
Lysates were clarified by centrifugation at 4 for 15 minutes at 15 OOOg. The 
resulting supematants were frozen at -20 or used immediately. Aliquots of the 
supematants were used for protein concentration determination by the standard 
bicinchoninic acid assay kit (Pierce, Rockford，IL). 
2.4.2 SDS'PAGE and immunodetection 
Samples (30 - 100 i^g protein) were denatured in Laemmli buffer and resolved 
on 10 or 13% sodium docecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
minigels, followed by electrophoretic transfer to nitrocellulose membranes (Hybond 
ECL; Amersham, Buckinghamshire, UK). The membranes were blocked for 1 h in 
Tris-buffered saline with 0.1% Tween-20 containing 5% non-fat dry milk. 
Immunodetection was performed by overnight incubation at 4 with primary 
antibodies diluted in the same blocking buffer. Primary antibodies to PARP, caspase-3, 
caspase-6, caspase-7, caspase-8, caspase-9, caspase-10, BC1-XL, Bak, Bad, Bim, Bid, 
were obtained from Cell Signalling Technology, Beverly, MA. Antibodies to Bcl-2 
and Bax were purchased from BD Biosciences, while antibody to P-actin was 
obtained from Sigma. After extensive washing, the blots were probed with 
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horseradish peroxidase-conjugated secondary antibodies (Cell Signalling Technology) 
for 1 hour at room temperature, and proteins were visualized by enhanced 
chemiluminescence (Cell Signalling Technology). Primary antibodies were employed 
at a 1:250 to 1:5000 dilution, and secondary antibodies were employed at a 1:2000 
dilution. 
2.5 Analysis of mitochondrial membrane potential 
Effect of SeC on the mitochondrial membrane potential of Sup-Ti cells was 
analyzed by Beckman Coulter Epics XL-MCL flow cytometer, with the application of 
5,5',6,6'-tetrachloro-l,r,3,3'-tetraethylbenzimidazolylcarbo-cyanine iodide (JC-1; 
Invitrogen Molecular ProbesTM，Carlsbad, CA). 2 ml cancer cells (5 x 10^ cells/mL) 
were incubated with SeC (0, 5, 10，20, 40，80 or 160 |iM) for 72 h for dose effect, and 
with SeC (0 or 20 nM) for 1，2，4，6，8，12, 24, 36, 48，60 and 72 h for time effect 
studies. They were then harvested and subjected to JC-1 staining and flow cytometric 
analysis. One million cells were then harvested and the dissociated cells were stained 
by 10 ng/ml JC-1 at 37°C for 10 min. The stained cells were then washed once, 
resuspended with PBS, and analyzed by the flow cytometer. Red fluorescence from 
JC-1 aggregates was measured at 590 nm and green fluorescence from JC-1 
monomers was measured at 530 nm. Data were displayed as the percentage of cells 
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with depolarized mitochondrial membrane. 
2.6 Measurement of ROS generation 
Effect of SeC on intracellular ROS generation was analyzed by Beckman Coulter 
Epics XL-MCL flow cytometer, with the application of dihydroethidium (DHE; 
Sigma, St.Louis, MO, USA). Intracellular superoxide (02~) levels were determined by 
the superoxide sensitive dihidroethidium (DHE) probe which is cell permeable and 
reacts with superoxide to form ethidium (Munzel et al” 2002). Briefly, the cancer 
cells (5 X 10^  cells/mL) were incubated with SeC (0 or 20 |LIM) for 5 min, 15 min, 30 
min, 1 h, 3 h, 6 h, 12 h or 24 h. The cells were then harvested by centrifugation, 
washed twice and resuspended in phosphate-buffered saline (PBS). Cell suspension 
was incubated with 10 i^M DHE at 37°C for 15 min analyzed by flow cytometry at 
610 nm. Percentage of cells with DHE fluoresence in each treatment was converted 
into fold changes of the control. 
2.7 Verification of ROS generation via the addition of 7V-Acetyl-L-cysteine and 
glutathione 
To verify the effect of cellular ROS, thiol reducing agents: glutathione (GSH; 
Sigma, St.Louis, MO, USA) and TV-Acetyl-L-cysteine (NAC; Sigma, St.Louis, MO, 
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USA) at 0.5, 1, 2 or 4 mM were pre-incubated with cells 4 h prior SeC treatment at 20 
f-iM for a farther incubation of 36 h. Cells were then harvested for measurement of 
MTT assay (Section 2.2)，apoptosis induction by measuring PI fluorescence on the 
Epics XL-MCL flow cytometer (Section 2.3)，and measurement of ROS (Section 2.6). 
2.8 Statistical analysis 
Results were expressed as mean 士 standard deviation (S.D.) and analyzed by 
Student's /-test. The level of significance was taken at p<0.05, p<0.01 and pcO.OOl. 
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Chapter 3 Results 
3.1 SeC induces prominent growth inhibition on Sup-Ti 
Various selenocompounds namely sodium selenate, sodium selenite and 
selenocystine were incubated with a panel of T-ALL cells, including, Sup-Ti, HSB-2 
and MOLT-3 for 72 h, which were then analyzed by MTT assay. Among the 
selenocompounds tested, sodium selenate showed poor growth inhibitory effect, with 
IC50 ranging from 200 to 300 |iM (Fig 3.1). Sodium selenite showed the most 
prominent growth inhibition on the T-ALL cells, with IC50 ranging from 5 to 10 _ 
(Fig 3.2). Selenite has been widely studied for its ability to induce DNA strand breaks 
and base damage at high concentrations in various cancer cells (Lu et al., 1994, Lu et 
fl/.，1995). Zhou et al (2003) found that inorganic selenite induced chromosomal 
DNA strand breaks and subsequently triggered cell apoptotic pathways. Selenite has 
been reported to induce apoptosis in human lymphoblastic cells. Despite the 
consistent growth inhibition with an low IC50 of selenite on all three T-ALL cell lines 
tested, previous findings revealed that selenite generates active oxygen species and 
causes cellular damage in the presence of sulfhydryl compounds compounds, such as 
cysteine or GSH and caused cellular damage in human cells (Terada et al., 1999). Due 
to its toxicity, research has been directed to natural of synthetic organic 
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selenocompounds. Here, organic selenocystine (SeC) showed similar growth 
inhibitory effect on Sup-Ti as seleinite, in a dose-dependent manner, significantly 
inhibiting the growth of Sup-TI by 69% at 20 |LIM. Selenocystine has been reported to 
induce cytotoxic effects on human leukemia cells in early 1980, however, the 
mechanism of selenocystine for leukemia treatment has not yet been elucidated. 
Previously, selenite was shown to be highly toxic to a panel of eight human cancer 
cell and normal human fibroblast cell, whereas selenocystine remaining marginally 
cytotoxic to normal human fibroblast cell (Chen and Wong, 2009). With a good 
understanding of the in vitro mechanism of selenocystine on susceptible leukemic 
cells, it could possibly pave the way to apply selenocystine as an alternative treatment 
for the leukemic patients if the in vivo studies are promising. Hence, selenocystine 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2 SeC induces S-phase arrest in cell cycle and triggers apoptosis in Sup-Ti 
As mentioned in section 3.1，SeC reduced the growth survival of Sup-Ti 
prominently after 72 h of incubation. In this study, by using DNA flow cytometry, 
cells in different cell-cycle phases were measured in the Sup-Ti cells and thus the 
regulation of SeC on cell cycle progression was elucidated (Figure 3.4). The cancer 
cells were treated with 0 to 160 |LIM of SeC, and incubated for 72 h, inhibiting 
growth survival of Sup-Ti significantly in a dose-dependent manner. SeC induced 
prominent accumulation of S-phase cells and depletion of G2/M - phase cells, at low 
dose as 5 |iM, that the accumulation for S-phase peaked at 10 |iM and the depletion 
peaked at 160 ^M (Fig. 3.4). At 10 \iM of incubation with SeC, the proportion of 
cells at S phase increased from the control 45.5 % to 63.7 %; the cells in G2/M phase 
at 160 ^iM, in meanwhile, reduced from 28.2% to 4.7% (Fig. 3.5). 
To study the time effect regulation of SeC on cell cycle progression, cancer 
cells were treated with or without 20 \iM of SeC, and incubated for 24 to 72 h. SeC 
induced prominent accumulation of S-phase cells and depletion of Go/i- phase cells, 
as early at 24 h (Fig. 3.6). At 24 h of incubation with SeC, the proportion of cells at 
S phase increased from the control 50.4 % to 66.6 %; the cells in Go/i phase, in 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.3 SeC triggers DNA fragmentation in Sup-Ti 
To investigate the mechanisms of growth inhibition, Sup-Ti was incubated with 
SeC (0-20 i^M) for 72 h. The cells undergone apoptosis were then identified with 
DNA-PI flow cytometry. The apoptotic cells, which had fragmented DNA were 
shown as sub-Gl in DNA histogram, were significantly increased by SeC at dosage 
as low as 5 ^iM (Figure 3.7), These apoptotic cells increased from 5.70% of total 
analyzed cells at 5 [xM to 25.67% at 160 |aM SeC (Figure 3.8). Time effect of SeC 
on inducing apoptosis was further investigated by treating cells with 20 jjM SeC for 
24, 36, 48, 60 and 72 h. DNA fragmentation was observed as early at 24 h of SeC 
treatment (Figure 3.9) SeC elevated the apoptotic cells by 3.4, 5.3，8.2，9.0，24.2% of 
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Fig. 3.8 Numeric data showing the dose effect of SeC on DNA 
fragmentation in Sup-Ti 
The cells were incubated with SeC (0, 5, 10, 20, 40, 80 or 160 ^iM) for 
72 h, and were then analyzed by flow cytometer. The cells with 
hypodiploid DNA content (sub-Gl population) were counted, and their 
numbers are expressed as a percentage of total population. Results are 
expressed as mean 士 SDs (n=3). Difference in means between the 
control and treatment groups was compared by Student's t-test; 
*P<0.05 and ***p<0.001. SeC elevated dose-dependently the sub-Gl 
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Fig. 3.9 Numeric data showing the time effect of SeC on DNA 
fragmentation in Sup-Ti 
The cells were incubated with SeC (0 or 20 \iM) for 24，36, 48，60 and 
72 h, and were then analyzed by flow cytometer. The cells with 
hypodiploid DNA content (sub-Gl population) were counted, and their 
numbers are expressed as a percentage of total population. Results are 
expressed as mean 士 SDs (n=3). Difference in means between the 
control and treatment groups was compared by Student's t-test, 
*P<0.05 and ***p<0.001. SeC elevated time-dependently the sub-Gl 
or apoptotic cells with fragmented DNA. 
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3.4 SeC induces PARP cleavage in Sup-Ti 
To confirm the ability of SeC to induce apoptosis in Sup-Ti, detection of PARP 
cleavage, which is one of the hallmark features of apoptosis, was performed by 
immunoblotting. Being compatible to the finding from DNA-PI flow cytometry 
(Figure 3.8)，5 ^M SeC was first found to induce cleavage of PARP into its smaller 
fragment (89 kDa), this cleavage persisted at higher doses and full cleavage was 
prominent at 20 ^M. (Figure 3.10). 
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Fig. 3.10 Immunoblot showing the effect of SeC on PARP cleavage in 
Sup-Ti 
The cells were incubated with SeC (0, 5，10 or 20 )LIM) for 72 h. 
P-Actin was measured as internal control to normalize expression of 
other proteins. One representative experiment of two is shown. SeC 
first induced PARP cleavage at 5 pM. 
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3.5 SeC activates caspases in Sup-Ti 
Activation of extrinsic and intrinsic apoptosis pathways has been well-studies 
as the major mechanism of apoptotic cell death in most cellular systems (Faded and 
Orrenius, 2005). The extrinsic death receptor pathway involves some death ligands 
binding to their receptor domains on the membrane surface to activate the initiator 
caspases (e.g. caspase-8 and -10). The intrinsic mitochondrial pathway, on the other 
hand, involves the induced mitochondrial stress which results in the release of 
apoptogenic factors from mitochondria into the cytosol to activate another initiator 
caspase, i.e. caspase-9. Both the extrinsic and intrinsic apoptosis pathways finally 
convert their signals to the activation of downstream effector caspases (e.g. 
caspase-3, -6 and -7) responsible for DNA fragmentation and cellular disintegration 
(Kumar, 1999; Nicholson, 1999). Since PARP is a substrate of effector caspases, its 
cleavage (Figure 3.10) indicated that caspases had been activated during the cell 
death process. Caspase activation involves cleavage of its procaspase. Caspase-9 of 
the intrinsic pathway and caspase-8 of the extrinsic pathway were cleaved, whereas 
procaspase-10 of the extrinsic pathway decreased after the SeC treatment, 
suggesting that this initiator caspases might be cleaved and thus activated during the 
cell death process. Besides, the effector caspase-3, -6 and -7 were also activated with 
the SeC treatment (Figure 3.11). 
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Caspase-9 is the leading caspase of the intrinsic pathway; whereas caspase-8 is 
the key initiator of the extrinsic pathway (Kumar, 2007). The immunoblot 
demonstrated that both caspase-8 and -9 were activated, indicating that both the 
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Fig. 3.11 Immunoblots showing the effect of SeC on caspase processing in 
Sup-Ti 
The cells were incubated with SeC (0’ 5, 10 or 20 ^iM) for 72 h. 
P-Actin was measured as internal control to normalize expression of 
other proteins. One representative experiment of two is shown. SeC 
induces caspase activation in caspase-3，-6, -7，-8 and 9，and might 
induce caspase-10 activation so that procaspase -10 was decreased. 
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3.6 SeC abrogates mitochondrial membrane potential in Sup-Ti cells 
Under normal circumstances, JC-1 exists as J-aggregates in the inner, polarized 
mitochondrial membrane and emits red fluorescence. Mitochondrial membrane 
depolarization, which occurs in the earlier stage of apoptosis, is observed when the 
mitochondria permeability transition pores open resulting in free distribution of ions 
between both sides of the membrane (Gross et al., 1999). As the mitochondrial 
membrane potential drops under apoptotic conditions, J-aggregates disintegrate and 
JC-1 exists as its green-fluorescent monomeric form. The ratio of green to red 
fluorescence emitted by JC-1 is therefore an indicator of extent of mitochondrial 
membrane depolarization (Bedner et al” 1999). 
To elucidate whether SeC triggered the intrinsic apoptosis pathway, the 
mitochondrial membrane potential was investigated with application of JC-1 and 
analysis by flow cytometer (Figure 3.12). Normally, JC-1 accumulates in active 
mitochondria in which it oligomerizes and fluoresces red. A reduction in 
mitochondrial membrane potential results in replacement of red JC-1 aggregates by 
green JC-1 monomers and increase in the mean green fluorescent intensity. Numeric 
data depicted that the percentage of cells with depolarized mitochondrial membrane 
elevated in a dose-dependent manner (Figure 3.13). The depolarized cells increased 
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Fig. 3.12 Representative histograms showing the dose effect of SeC on 
mitochondrial membrane potential in Sup-Ti 
The cells were incubated with SeC (0，5, 10，20, 40，80 or 160 _ for 
72 h. They were then harvested and subjected to JC-1 staining and flow cytometric analysis. 
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Fig. 3.13 Numeric data showing the dose effect of SeC on mitochondrial 
membrane potential in Sup-Ti 
The cells were incubated with SeC (0，5，10，20，40, 80 or 160 |liM) for 
72 h. They were then harvested and subjected to JC-1 staining and 
flow cytometric analysis. Percentage of cells with depolarized 
mitochondrial membrane is shown. Results are shown as mean values 
from 土 SDs (n=3). Difference in means between the control and 
treatment groups was compared by Student's t-test; *p<0.05 and 




Time effect of SeC on the mitochondrial membrane potential was also 
determined after 1,2, 4, 6, 8, 12, 24, 36, 48, 60 and 72 h of incubation. Numeric data 
depicted that the percentage of cells with depolarized mitochondrial membrane 
elevated in a time-dependent manner (Figure 3.14). The depolarized cells increased 
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Fig. 3.14 Numeric data showing the time effect of SeC on mitochondrial 
membrane potential in Sup-Ti 
The cells were incubated with SeC (0 or 20 _ for 1, 2, 4, 6，8，12， 
24, 36, 48，60 and 72 h. They were then harvested and subjected to 
JC-1 staining and flow cytometric analysis. Percentage of cells with 
depolarized mitochondrial membrane is shown. Results are shown as 
mean values from 土 SDs (n=3). Difference in means between the 
control and treatment groups was compared by Student's Mest; 
*P<0.05 and ***p<0.001. SeC elevated the cells with depolarized 
mitochondrial membrane time-dependently. 
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3.7 SeC modulates expressions of Bcl-2 members and activates Bim and Bid in 
Sup-Ti 
The Bcl-2 family proteins interact with each other to regulate the mitochondrial 
membrane permeability. To investigate how SeC induces the mitochondrial membrane 
depolarization, seven different pro- and anti-apoptotic Bcl-2 family proteins were 
investigated by immunoblotting. Bim have three isoforms of different apoptotic 
potencies, namely, BimeL (23kD) and BiniL (15kD) and Bims (12kD). BiniEL and 
BiiTiL, but not Bims, bind and sequester to LC8 of the microtubule-associated dynein 
motor complex, thereby blocking their pro-apoptotic activity under normal conditions 
(Puthalakath et al” 1999). Hence, Bims is the most effective killer. Se activates the 
pro-apoptotic Bim, which binds to and antagonizes the anti-apoptotic Bcl-2 family 
proteins including Bcl-2, BC1-XL and Mcl-l, or directly binds to and activates the 
pro-apoptotic Bax-like proteins (Marani et al., 2002). Initiation of intrinsic death 
pathway is eventually achieved by modulating the activities of Bcl-2 family proteins 
by Bim ultimately (Figure 3.15). 
Bcl-2 and BC1-XL preserve integrity of the outer mitochondrial membrane and 
thus prevents release of apoptogenic factors from mitochondria into the cytosol 
(Kluck et al” 1997)，it was proposed that Bcl-2 and BC1-XL might interfere with the 
function of cytochrome c / Apaf-1/ caspase-9 apoptosome complex via a direct 
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interaction of Bcl-2 or BC1-XL with Apaf-1. Phosphorylation of Bad through Akt/ 
protein kinase B inactivates Bad, the latter disrupts the binding of Bad to BC1-XL and 
results in Bax- and Bak-dependent apoptosis. Bax and Bak are two important 
multidomain pro-apoptotic proteins essential for the release (Eskes et al” 2000). SeC 
depleted the anti-apoptotic Bcl-2 and BC1-XL protein dose-dependently and elevated 
the pro-apoptotic Bax and Bak protein (Figure 3.15). 
Mitochondria participate in the SeC-induced apoptosis was shown via depletion 
of Bid protein. Bid is cleaved proteolytically by activated caspase-8 into truncated Bid， 
which then translocates to mitochondria and sensitizes mitochondrial damage and 
release of apoptogenic factors. Bid relays the extrinsic apoptotic signal from the cell 
surface to the intrinsic apoptotic signal in mitochondria (Heir and Debatin, 2001; 
Daniel et al., 2003). As shown in Figure 3.15, Bid was depleted after the SeC 
treatment. This truncated Bid, together with Bc l -2 and BC1-XL depletion and Bax and 
Bak elevation, would favor the mitochondrial membrane depolarization and discharge 
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Fig. 3.15 Immunoblots showing the effect of SeC on Bcl-2 family protein in 
Sup-Ti 
The cells were incubated with SeC (0，5, 10 or 20 ^iM) for 72 h. 
p-Actin was measured as internal control to normalize expression of 
other proteins. One representative experiment of two is shown. SeC 
induces SeC induces Bax, Bak, and Bim activation, and Bad, Bcl-2 
and BC1-XL depletion. 
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3.8 SeC induces ROS production in Sup-Ti 
Oxidative stress was reported to be a major mechanism of Se-induced cytotoxicity 
and apoptosis (Kim et al., 2003; Drake, 2006). ROS-triggered mitochondrial 
permeability transition also provides an alternative for the release of apoptogenic 
factors from mitochondria (Rosse et al., 1998). To testify this hypothesis, the 
intracellular ROS generation in cells incubated with SeC (0 or 20 ^M) for 5 min, 15 
min，30 min, 1 h, 3 h, 6 h, 12 h or 24 h was measured by DHE-flow cytometry. 
Time-course study showed prominent increase in the ROS generation as early as 
1710/0 of control at 3 h after SeC treatment, which increased time-dependently, 
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Fig. 3.16 Numeric data showing the time effect of SeC on cellular ROS level 
in Sup-Ti 
The cells were incubated with SeC (0 or 20 ^iM) for 5 min, 15 min, 30 
min，1 h, 3 h, 6 h, 12 h or 24 h. They were then harvested and 
subjected to DHE staining and flow cytometric analysis. Percentage of 
cells with DHE fluoresence is shown as fold of control. Results are 
shown as mean values from 土 SDs (n=3). Difference in means 
between the control and treatment groups was compared by Student's 
/-test; *p<0.05 and ***p<0.001. SeC induced ROS generation in 
Sup-Ti cells time-dependently. 
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3.9 Antioxidants protect Sup-Ti cells from SeC-induced growth inhibition 
To study the role of ROS in the SeC-induced growth inhibition, the leukemic 
cells were incubated with different combinations of SeC and two thiol-reducing 
antioxidants, glutathione (GSH) and //-Acetyl-L-cysteine (NAC) at 4，2, 1 and 0.5 
mM，4 hours prior administration of 20 _ SeC for 36 h, and subjected to MTT assay. 
NAC rescued the leukemic cells most effectively at dosage of 2 mM (Figure 3.17)， 
which coincided with the rescue of leukemic cells from SeC-induced DNA 
fragmentation (Figure 3.19), suggesting it to be the optimal dose. GSH rescued the 
leukemic cells best at 4 mM (Figure 3.18), yet at 2 mM, an increase of growth 
inhibition was shown to be slightly greater than 1 mM, which may be the result of 
SeC oxidation of GSH, which resulted in the accumulation of ROS, which led to 
oxidative DNA damage and eventually growth inhibition. 
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Fig. 3.17 Numeric data showing the growth inhibitory effect of SeC, treated 
with antioxidant on Sup-Ti 
The cells were preincubated with the thiol-reducing antioxidant, 
A^-Acetyl-L-cysteine (NAC) at 4, 2, 1 and 0.5 mM, 4 hours prior 
administration of SeC (20 36 h). They were then harvested and 
subjected to MTT assay. Results are expressed as the percentage of 
growth inhibition compared with their corresponding controls. Results 
are expressed as mean 士 SDs (n=3). Difference in means between the 
control and treatment groups was compared by Student's /-test; 
*P<0.05, **p<0.01 and ***p<0.001. NAC rescued leukemic cells from 
SeC-induced growth inhibition most effectively at 2 mM. 
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Fig. 3.18 Numeric data showing the growth inhibitory effect of SeC, treated 
with antioxidant on Sup-Ti 
The cells were preincubated with the thiol-reducing antioxidant, 
glutathione (GSH) at 4，2, 1 and 0.5 mM, 4 hours prior administration 
of SeC (20 |lIM, 36 h). They were then harvested and subjected to 
MTT assay. Results are expressed as the percentage of growth 
inhibition compared with their corresponding controls. Results are 
expressed as mean 土 SDs (n=3). Difference in means between the 
control and treatment groups was compared by Student's 广test; 
*P<0.05, **p<0.01 and ***p<0.001. GSH rescued leukemic cells from 
SeC-induced growth inhibition most effectively at 4 mM. 
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3.10 Antioxidants protect Sup-Ti cells from SeC-induced apoptosis 
To further examine the importance ofROS generation in SeC-induced apoptosis, 
following the protective effect on growth inhibition, we next investigate the effects of 
a thiol-reducing antioxidant A^-Acetyl-L-cysteine (NAC) and glutathione (GSH) on 
the apoptotic cell death. 2 mM NAC (Figure 3.19) and 4 mM GSH (Figure 3.20) 
completely blocked the increase in sub-Gl cell populations caused by SeC, relative to 
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Fig. 3.19 Numeric data showing the DNA fragmentation effect of SeC, 
treated with antioxidant on Sup-Ti 
The cells were preincubated with the thiol-reducing antioxidant, 
A^-Acetyl-L-cysteine (NAC) at 4, 2 and 1 mM, 4 hours prior 
administration of SeC (20 |LIM, 36h). They were then harvested and 
analyzed by flow cytometer. The cells with hypodiploid DNA content 
(sub-Gl population) were counted, and their numbers are expressed as 
a percentage of total population. Results are expressed as mean 土 SDs 
(n=3). Difference in means between the control and treatment groups 
was compared by Student's t-test; *p<0.05 and ***p<0.001. SeC 
elevated dose-dependently the sub-Gl or apoptotic cells with 
fragmented DNA. NAC rescued leukemic cells from SeC-induced 
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Fig. 3.20 Numeric data showing the DNA fragmentation effect of SeC, 
treated with antioxidant on Sup-Ti 
The cells were preincubated with the thiol-reducing antioxidant, 
glutathione (GSH) at 4, 2 and 1 mM, 4 hours prior administration of 
SeC (20 |XM, 36 h). They were then harvested and analyzed by flow 
cytometer. The cells with hypodiploid DNA content (sub-Gl 
population) were counted, and their numbers are expressed as a 
percentage of total population. Results are expressed as mean 士 SDs 
(n=3). Difference in means between the control and treatment groups 
was compared by Student's Mest; *p<0.05, **p<0.01 and ***p<0.001. 
GSH rescued leukemic cells from SeC-induced DNA fragmentation 
most effectively at 4 mM. 
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3.11 Antioxidants effectively block SeC-induced ROS generation in Sup-Ti cells 
To further examine the role of ROS in SeC-induced apoptosis, the effects of 
anioxidants on intracellular ROS generation were examined. Both antioxidants NAC 
(Figure 3.22) and GSH (Figure 3.21) could inhibit intracellular ROS generation to 
various extents, with 4 mM GSH (Figure 3.21) showing the best effect, almost 
reducing its level comparable to that of control. These results of antioxidants showing 
the ability to inhibit intracellular ROS generation induced by SeC, coincides with the 
results shown previously of the protective effects of the antioxidants to protect Sup-Ti 
cells from SeC-induced growth inhibition (Figure 3.17 and 3.18) and DNA 




* * * 
？ 500 -
0) 
I I . ！ I 3 0 0 - I 
E f 200 - • ‘ • 
_ i 100 • i i I 
。已 1�: I j L J L j l m j l J l I L I L 
SeC + - • + + + 
GSH - - 4 mM 2 mM 1 mM 4 mM 2 mM 1 mM 
Concentration of SeC and GSH 
Fig. 3.21 Numeric data showing the intracellular ROS level in Sup-Ti, 
treated with antioxidant 
The cells were preincubated with the thiol-reducing antioxidant, 
glutathione (GSH) at 4, 2 and 1 mM, 4 hours prior administration of 
SeC (20 36 h). They were then harvested and subjected to DHE 
staining and flow cytometric analysis. Percentage of cells with DHE 
fluoresence is shown as fold of control. Results are shown as mean 
values from 土 SDs (n=3). Difference in means between the control 
and treatment groups was compared by Student's Mest; *p<0.05 and 
***p<0.001. SeC induced ROS generation in Sup-Ti cells was 
reduced by GSH most effectively at 4 mM. 
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Fig. 3.22 Numeric data showing the intracellular ROS level in Sup-Ti, 
treated with antioxidant 
The cells were preincubated with the thiol-reducing antioxidant, 
A^-Acetyl-L-cysteine (NAC) at 4 mM, 2 mM and 1 mM, 4 hours prior 
administration of SeC (20 |LIM, 36 h). They were then harvested and 
subjected to DHE staining and flow cytometric analysis. Percentage of 
cells with DHE fluoresence is shown as fold of control. Results are 
shown as mean values from 士 SDs (n=3). Difference in means 
between the control and treatment groups was compared by Student's 
/-test; *p<0.05 and ***p<0.001. SeC induced ROS generation in 
Sup-Ti cells was reduced partially at various concentrations of NAC. 
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3.12 SeC induces mitochondrial membrane permeabilization via ROS-mediated 
mechanisms Sup-Ti cells 
As found previously, both antioxidants NAC and GSH could inhibit SeC-induced 
intracellular ROS generation, protect Sup-Ti cells from SeC-induced growth 
inhibition and DNA fragmentation. To study the role of ROS in the SeC-induced 
mitochondrial apoptosis, Sup-Ti cells were incubated with different combinations of 
antioxidants, GSH and NAC, and subjected to mitochondrial membrane 
depolarization measurement by JC-1 analysis, as it is a crucial step in the 
mitochondrial apoptotic pathway. Results showed SeC-induced mitochondrial 
membrane depolarization was reduced by both GSH and NAC to various extent at 
corresponding dosage at 1, 2 and 4 mM (Figure 3.23 and 3.24). Mitochondrial 
membrane depolarization was most efficiently reduced to control levels by 4 mM 
GSH (Figure 3.23). In conclusion, ROS-mediated DNA damage is involved in 
SeC-induced apoptosis 
In summary, SeC induced apoptosis in Sup-Ti cells, mediated by the intrinsic 
apoptotic pathway evident by mitochondrial membrane depolarization, as early as 4 h 
after SeC treatment, which coincides with the modulation of Bcl-2 family proteins, 
which are common initiator of the intrinsic apoptotic pathway. Intracellular ROS level 
elevated as after 3 h of SeC treatment, an hour before the mitochondrial membrane 
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depolaraization took place. ROS behaves as an initiator of the SeC-induced 
mitochondrial apoptotic pathway, able to be inhibited by antioxidant. 
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Fig. 3.23 Numeric data showing the effect of SeC on mitochondrial 
membrane potential in Sup-Ti, treated with antioxidant 
The cells were preincubated with the thiol-reducing antioxidant, 
glutathione (GSH), at 4, 2 and 1 mM, 4 hours prior administration of 
SeC (20 ^M, 36 h). They were then harvested and subjected to JC-1 
staining and flow cytometric analysis. Percentage of cells with 
depolarized mitochondrial membrane is shown. Results are shown as 
mean values from 土 SDs (n=3). Difference in means between the 
control and treatment groups was compared by Student's 广test; 
*p<0.05 and ***p<0.001. GSH reduced the amount of cells with 
mitochondrial membrane depolarization most effectively at 4 mM. 
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Fig. 3.24 Numeric data showing the effect of SeC on mitochondrial 
membrane potential in Sup-Ti，treated with antioxidant 
The cells were preincubated with the thiol-reducing antioxidant, 
A^-Acetyl-L-cysteine (NAC) at 4, 2 and 1 mM, 4 hours prior 
administration of SeC (20 |nM, 36 h). They were then harvested and 
subjected to JC-1 staining and flow cytometric analysis. Percentage of 
cells with depolarized mitochondrial membrane is shown. Results are 
shown as mean values from 土 SDs (n=3). Difference in means 
between the control and treatment groups was compared by Student's 
/-test; *p<0.05 and ***p<0.001. NAC reduced the amount of cells with 
mitochondrial membrane depolarization most effectively at 1 mM. 
78 
Chapter 1 
Chapter 4. Discussion 
Cancer is a leading cause of death worldwide. According to the World Health 
Organization (WHO), malignant tumors were responsible for 12 per cent of the nearly 
56 million deaths worldwide from all causes in the year 2000 (Mathers et al, 2001) 
and it accounted for 13 per cent of the nearly 61 million deaths worldwide in 2007. 
Aberrations in apoptotic pathways have been detected in a variety of cancers, 
suggesting that loss of the ability of cells to undergo apoptosis may contribute to 
carcinogenesis. Since cancer therapies such as radiation, glucocorticoids, and 
chemotherapeutic drugs exert their beneficial effects, at least in part, by inducing 
apoptosis in the cancer cells, the same aberrations in apoptotic pathways would be 
predicted to contribute to resistance (Kaulmann and Vaux, 2003). 
The occurrence of multidrug resistance (Gottesman and Pastan, 1993), the 
metastatic properties of cancer cells (Aziz et al, 2003; Eccles and Welch, 2007) and 
the lack of selective cytotoxicity of anticancer drug (Crighton and Ryan, 2004; de 
Bono et al 2003) encountered by the current cancer treatment limit the drug dosage to 
a tolerable yet effective level. Consequently, a turn from relying on the major 
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chemotherapeutics to the discovery and use of medicinal compounds from natural 
products could have provided alternative choices for cancer patients (Smith et al” 
1999). Since 1960, over 50% of anticancer drugs approved by the United States Food 
and Drug Administration (FDA) were originated from the natural resources, 
especially from terrestrial plants (Kim and Park, 2002). In addition to being the major 
chemotherapeutics, phytochemicals have been increasingly recognized as 
chemopreventive agents (Aziz et al., 2003; Surh, 2003). 
Despite the adverse risk associated with T-lineage ALL has progressively been 
overwhelmed by intensive chemotherapeutic regimens, approximately 20% of the 
patients with T-ALL continue to fail the therapy. Higher rate of induction failure and 
early relapse in these patients suggest that their blast cells are more inherently 
resistant to conventional chemotherapeutic agents. Further augmentation of the 
currently used intensive chemotherapeutic regimens may not be warranted because of 
the likelihood of significant adverse effects. Thus, the identification of additional 
prognostic variables which can bypass the chemoresistance mechanisms might 
provide cures for the chemoresistant T-ALL. 
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Se is an essential trace element of fundamental importance to human and 
many other forms of life (Rayman, 2000). Epidemiological studies, preclinical 
investigations and clinical intervention trials support the role of Se compounds as 
potent cancer chemopreventive agents (Sinha and El-Bayoumy, 2004). 
Previously, seleoncystine, SeC, a nutritionally available selenoamino acid, was 
identified as a novel agent with broad spectrum antitumor activity. A panel of eight 
human caner cell lines was shown to be susceptible to SeC, yet remaining marginally 
cytotoxic to normal human fibroblast cell (Chen and Wong, 2009). Here, SeC was 
first shown in the present investigation to inhibit the growth of T-ALL cell line, 
Sup-Ti • In the beginning, a panel of selenocompounds, namely, sodium selenite, 
sodium selenate and seleoncystine were incubated with a panel of T-ALL cells, 
including, Sup-Ti, HSB-2 and MOLT-3 for 72 h, growth inhibitory effect were then 
analyzed by MTT assay. Among the selenocompounds tested, sodium selenite showed 
the most prominent growth inhibition on all T-ALL cells, with IC50 ranging from 5 to 
10 |iM. Selenite has been reported to induce apoptosis in human lymphoblastic cells. 
However, the potency of organic selenocystine for leukemia treatment has not yet 
been elucidated. Here, selenocystine which showed similar growth inhibitory effect as 
selenite on Sup-T! was chosen for further investigation. 
Response of Sup-Ti cells to the antiproliferative and cytotoxic actions of SeC 
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seem to occur in a dose-dependent manner. Furthermore, DNA flow cytometry was 
performed to examine the dose and time effects of SeC on cell cycle and apoptosis, 
the main processes which modulate tumor development. Flow cytometric results 
revealed that the antiproliferative action of SeC was associated with the primitive 
accumulation of cells at S phase of cell cycle at 5 ]xM, 72 h, and shortly after 24 h of 
20 |.iM of SeC incubation. The S-phase arrest in dose effect was accompanied by 
depletion of G2 cells, while in time effect, was accompanied by depletion of Gi cells. 
These results suggest that some cells were delayed or forced to complete the cell cycle 
without re-entering G2 or Gi phase correspondingly. This abnormal termination of cell 
cycle triggers some of the arrested cells to undergo apoptosis. Concurrently, the 
apoptotic population accumulated exponentially under prolonged SeC treatment. The 
appearance of apoptotic cells briefly after S-phase arrest suggested the importance of 
apoptosis induction in cell growth control induced by SeC. Therefore, the apoptotic 
mechanisms of SeC-induced cell death were further investigated. 
The incidence of apoptosis was revealed as hyplodploid or apoptotic 
population in the DNA histogram in the flow cytometric analysis. The apoptotic 
population was identified by flow cytometry according to the occurence of DNA 
fragmentation, being one of the morphological hallmarks of apoptosis. Apoptosis was 
characterized by several physical and biochemical features. Physically, apoptotic cells 
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displays chromatin condensation, DNA fragmentation and cell shrinkage (Ziegler and 
Groscurth, 2004). Biochemically, caspases will be activated proteolytically and 
breaking down cells. The SeC-induced apoptosis was confirmed biochemically by the 
study of caspase activation via immunoblot studies. SeC induced caspase-7, -9, -8, -10, 
-3, -6 activation. Both the death-receptor mediated extrinsic pathway and the 
mitochondrion-mediated intrinsic pathway were induced, evidenced by activation of 
caspase-8, the initiator caspase of the extrinsic pathway, and the activation of 
caspase-9, the first proteolytic signal in the intrinsic pathway (Riedl and Salvesen, 
2007). Caspase-8 is activated by the DISC formation composing the death-inducing 
ligand, death receptor, death domain containing molecule and procaspase-8 
(Kumbanov et. al” 2005). Activated caspase-8 thereby truncates Bid, relaying the 
extrinsic pathway with the intrinsic pathway. 
Caspase-9 activation is a strong indicator of the elicitation of the mitochondrion 
mediated apoptosis. The activation of caspase-9 is the first proteolytic signal in the 
intrinsic apoptotic pathway (Riedl and Salvesen, 2007). Unlike the initiator caspase-8 
in the extrinsic apoptotic pathway that is activated by transmembrane receptor, 
caspase-9 is activated by the cytosolic complex called apoptosome. Apoptosome 
composes of several molecules, including Apaf-1, cytochrome c, ATP or 2'-deoxyATP 
(dATP) (Shi, 2006). The apoptosome formed will then recruit and activate caspase-9, 
83 
Chapter 1 
which performs the subsequent cleavage of apoptotic substrates. In this circumstance, 
the release of cytochrome c from mitochondria into the cytosol becomes critical, not 
only because cytochrome c is one of the components of apoptosome, but also it 
triggers the self-inhibited and monomeric Apaf -1 molecules to oligomerize and 
initiate the apoptosome formation (Riedl et al., 2005). Release of cytochrome c from 
mitochondria indicates the mitochondrial dysfunction. Hence, the release of 
mitochondrial cytochrome c to the cytosol is a key event of execution of the intrinsic 
apoptotic pathway. To detect the execution of mitochondrial pathway in SeC-induced 
apoptosis, mitochondrial membrane potential was measured by flow cytometry. Here, 
we showed that mitochondrial membrane depolarization at 5 |LIM, 72 h SeC treatment 
and as early as 4 h of 20 i^M SeC treatment. Hence, the mitochondrial pathway is also 
induced in SeC-induced apoptosis in Sup-T! cells. 
To discover the regulators of mitochondrial dysftinction in SeC-induced 
apoptosis, the central regulator of apoptosis, Bcl-2 family members are studied via 
immunoblot analysis. The Bcl-2 family members intergrate diverse survival and death 
signals into the mitochondrial membranes. In this family of proteins, members are 
sub-divided into anti-apoptotic members, e.g. Bcl-2, BC1-XL, and pro-apoptotic 
members, e.g. Bax, Bim, which regulates apoptosis by interacting with each other. 
The well-characterized candidates such as Bcl-2 and Bax have been reported to be 
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involved in mitochondrial membrane depolarization and thus facilitate the release of 
cytochrome c (Rosse et al, 1998). Having such an important role in the 
mitochondrion-mediated apoptosis, some better characterized members of the Bcl-2 
family were studied. They are the anti-apoptotic Bcl-2 and BC1-XL, proapoptotic Bax, 
Bad and BiniEL, as well as the linker of the two apoptotic pathways Bid. 
Members from the two branches interact with each other and regulate different 
aspects of apoptosis. The well-characterized candidates such as Bcl-2 and Bax have 
been reported to be involved in mitochondrial membrane depolarization and thus 
facilitate the release of cytochrome c (Rosse et al., 1998). Having such an important 
role in the mitochondrion-mediated apoptosis, some better characterized members of 
the Bcl-2 family were studied. They are the anti-apoptotic Bcl-2 and BC1-XL, 
proapoptotic Bax, Bad and BirriEL, as well as the linker of the two apoptotic pathways 
Bid. Immunoblot results showed that SeC depleted the anti-apoptotic Bcl-2 and 
BC1-XL protein dose-dependently and elevated the pro-apoptotic Bax and Bak protein. 
Bid is cleaved proteolytically by activated caspase-8 into truncated Bid, which then 
translocates to mitochondria and sensitizes mitochondrial damage and release of 
apoptogenic factors. This truncated Bid, together with Bcl-2 depletion and Bax and 
Bak elevation, favor the mitochondrial membrane depolarization and discharge of 




ROS has been recently identified to play a regulatory role in apoptosis (Ott et al., 
2007). Excess damaging ROS unable to be eradicated by the innate antioxidative 
systems, results in oxidative stress to cell (Liu et al, 2002). ROS also oxidizes the 
lipids in membrane and damage DNA. ROS disturbs the normal mitochondrial proton 
gradient, resulting in loss of membrane potential and release of apoptogenic factors 
(Kowaltowski, 1996). Our results showed that ROS was elevated in SeC-treated cells, 
and the thiol-reducing antioxidants, glutathione and 7V-Acetyl-L-cysteine, were able to 
inhibit the intracellular ROS generation. In addition, the mitochondrial membrane 
depolarization was reduced by the antioxidant. Interestingly, growth inhibitory effect 
and DNA fragmentation was also rescued by the antioxidant. The results suggested 
that ROS mediates DNA damage, playing a regulatory part in the mitochondrial 




To conclude, this study has proposed a comprehensive mechanism for the 
growth inhibitory effect of SeC on Sup-Ti cells. SeC retards the growth of cancer 
cells by arresting them at S-phase, thereby disturbing the cell cycle progression. Such 
abnormal condition leads to apoptosis. Here, both the extrinsic and intrinsic apoptotic 
pathways are activated. SeC induced caspase-8 activation of the extrinsic pathway, 
bringing about Bid truncation which relays the intrinsic pathway. The initiator caspase 
of intrinsic pathway, caspase-9 is also activated, alongside with ROS generation 
quickly after 3 h treatment before mitochondrial membrane depolarization at 4h 
treatment of SeC. Intracellular ROS was shown to be essential for SeC-induced 
growth inhibition, apoptosis and mitochondrial membrane depolarization. It is 
reasonable to propose that ROS generation is a crucial event induced by SeC, 
upstream of DNA fragmentation and apoptosis. ROS serves as a mediator of the 
signaling pathway of SeC-induced apoptosis, which results in the mitochondrial 
membrane depolarization and cytochrome c release. The two pathways finally 
converge into the activation of the effector caspase-3, PARP cleavage and DNA 
fragmentation. Here, we show that the possibility of development of SeC into a potent 
anticancer candidate, which can combat the chemoresistance in T-ALL. 
With a good understanding of the in vitro mechanism of SeC on leukemic 
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cells, we anticipate that SeC has the potential to be applied as an alternative treatment 
for the leukemic patients that can overcome T-ALL cells resistant to drug-induced 
apoptosis. Findings of this study facilitate the development of novel treatment 
regimens or strategies against drug-resistant T-ALL patients which paves the path for 
further in vivo studies on SeC, and eventually develop SeC as an alternative treatment 
for leukemic patients. Furthermore, combination treatment which is a common way of 
treatment of SeC and conventional drugs might be a possible strategy to combat the 
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Fig. 4.1 Overview of proposed mechanism in SeC-induced apoptosis in 
Sup-Ti cells 
SeC induced S-phase arrest and subsequent apoptosis in Sup-Ti cells via 
both the extrinsic and intrinsic pathway. SeC activated of caspase-8 and 
10. On the other hand, SeC induced the production of ROS which act as 
the major regulator controlling the intrinsic apoptotic pathway. The 
activated caspase-8 processes and activates Bid, which relays the signals 
from the extrinsic to the intrinsic apoptosis pathways with activation of 
caspase-9. Depletion of Bcl-2, BC1-XL and Bad and elevation of Bax, 
Bak and Bim seem to be the major regulators controlling the intrinsic 
apoptosis pathway. Both the death receptor and the mitochondrial 
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